Navigation Links
American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
Date:1/26/2011

GERMANTOWN, Md., Jan. 26, 2011 /PRNewswire/ -- RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.  

Dr. Stanley Jones, the surgeon and patient, reports that he had a sudden onset of acute pain in his wrist in September 2009; shortly thereafter the patient experiences pain in his knees as well.  Dr. Jones saw a rheumatologist who diagnosed him with Autoimmune Arthritis.  He was placed on Cortisone, a steroid hormone, to suppress immune response and alleviate pain.  Unfortunately Dr. Jones suffered complications from the Cortisone including chest pain and Candidiasis which were unbearable.  His condition deteriorated and his ability to perform routine activities of daily living or his profession was impacted.  

After visiting many physicians and talking with experts in the field, Dr. Jones was introduced to RNL Bio's stem cell therapy.  After a workup, he received stem cell infusions in Kyoto, Japan in May 2010.  Post infusion, he began to notice improvement and by the 5 month, he had a complete recovery and was able to resume sports as well as operating!  In addition, he no longer needed any medications including Cortisone or Methotrexate.  Dr. Jones' rheumatologist in Houston saw Dr. Jones post infusion and said, "It is amazing that Dr. Jones was able to experience improvement from cutting-edge medical technology."

Other patients treated by the company have had very successful results as reported by RNL BIO Co., Ltd in 2009, an American artist, John Cullison's stem cell treatment for Rheumatoid Arthritis, and in September 2010, Japanese Yosida's treatment for psoriasis.

About RNL BIO CO., LTD.

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell therapies.  RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis and one phase I trial for spinal cord injury.  RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.

Video Interview Link:

http://www.youtube.com/watch?v=xzDElPr9gRo

Related Link:

http://www.rnl.co.kr/eng/main.asp


'/>"/>
SOURCE RNL BIO CO., LTD.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineerings CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintaos Delegation
2. Maldonado Medicals Green Initiative, a Model for the American Small Business
3. American Medical Systems Launches STEP Patient Education Program in Europe
4. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
5. Amarin Announces Successful Completion of Offering of American Depositary Shares
6. Amarin Prices Public Offering of American Depositary Shares
7. Pharmacists Encourage Americans to Consider Medicine Cabinet Cleanout Among New Years Resolutions
8. CVS CAREMARK to Purchase Universal Americans Medicare Part D Business
9. American Regent Initiates Nationwide Voluntary Recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%, 50 mL Single Dose Vials Due to Particulate Matter
10. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
11. Red Cross Supports Pan American Health Organization with $1.5 Million in Medicine and Supplies for Cholera Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. ... drug, OXS-1550, was described as a "clinical trial triumph" ... drug went into complete cancer remission. ... of Minnesota Masonic Cancer Center. --> ... of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... Massachusetts (PRWEB) , ... February 10, 2016 , ... ... models to effectively measure change in their patients. Research shows that the Goal ... methods. To help therapists overcome this challenge and learn more about the Goal ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... has been awarded the prestigious Distinguished Emerald Club of the World award, as ... BoardRoom magazine, one of the most respected trade publications serving private clubs. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – ... – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has ... state still face a lot of restrictions as to where they can smoke pot. ... personal use” and that cannabis “may not be consumed openly or publicly.” , Given ...
(Date:2/10/2016)... Puente, California (PRWEB) , ... February 09, 2016 ... ... Medicine students, faculty and staff helped give free oral screenings to 150 children ... Feb. 5, 2016. , The College of Dental Medicine joined Chinese American Dental ...
Breaking Medicine News(10 mins):